9,10-Dihydro-4H-benzo<4,5>cyclohepta<1,2-b>thiophen-10-one | 60587-38-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 环七噻吩
• 英文名称: 9,10-Dihydro-4H-benzo<4,5>cyclohepta<1,2-b>thiophen-10-one
• 英文别名: 6-Thiatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaen-8-one
• CAS: 60587-38-4
• 化学式: C₁₃H₁₀OS
• 分子量: 214.288
• InChiKey: MMHDAZZFENXBCE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  45.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-(3-Thenyl)benzyl bromide 在 potassium cyanide 、 五氯化磷 、 四氯化锡 作用下， 以 水 、 苯 为溶剂， 反应 6.0h， 生成 9,10-Dihydro-4H-benzo<4,5>cyclohepta<1,2-b>thiophen-10-one
  参考文献：
  名称：

  Majchrzak, Michal W., Journal of Heterocyclic Chemistry, 1985, vol. 22, p. 1203 - 1204

  摘要：

  DOI：

文献信息

• Carbostyril derivatives and antiallergic agent
  申请人：SAWAI PHARMACEUTICAL CO., LTD.

  公开号：EP0577325A1

  公开（公告）日：1994-01-05

  1. A compound of the formula: wherein the symbol of a solid line with a broken line means a single bond or a double bond, R and R' are independently selected from the group consisting of hydrogen atom, halogen atom, lower alkyl, nitro, unsubstituted amino and substituted amino, A and B are independently selected from the group consisting of hydrogen atom, lower alkyl optionally substituted with a lower cycloalkyl, aryl optionally substituted with one or more halogen atoms and the group: -Y-R² wherein Y is lower alkylene and R² is the group: wherein m is integer of 1 to 3, n is 0 or 1, Z is >N-, >CH- or >C=, R³ is diaryl(lower)alkyl optionally substituted with one or more halogen atoms or is condensed heterocyclic group optionally substituted with oxo, with the proviso that (a) at least one of A and B is the group -Y-R², and (b) when A is hydrogen atom and B is the group -Y-R², then Z is >CH- or >C= if R³ is condensed heterocyclic group optionally substituted with oxo and n is O or a pharmaceutically acceptable salt thereof. The compounds of the above formula have antiallergic activity.

  1.式中的化合物： 其中实线与断线的符号表示单键或双键、 R和R'独立地选自由氢原子、卤素原子、低级烷基、硝基、未取代氨基和取代氨基组成的组、 A 和 B 独立地选自由氢原子、任选被低级环烷基取代的低级烷基、任选被一个或多个卤素原子取代的芳基以及以下基团组成的组中：-Y-R² 其中 Y 为低级亚烷基，R² 为以下基团： 其中 m 为 1 至 3 的整数，n 为 0 或 1，Z 为 >N-、>CH- 或 >C=，R³ 为二芳基（低级）烷基，可任选被一个或多个卤素原子取代，或为缩合杂环基团，可任选被氧代取代，但条件是 (a) A 和 B 中至少有一个是基团-Y-R²，且 (b) 当 A 为氢原子，B 为基团-Y-R² 时，如果 R³ 为可选被氧代取代的缩合杂环基团且 n 为 O，则 Z 为 >CH- 或 >C= 或其药学上可接受的盐。上式化合物具有抗过敏活性。
• MAJCHRZAK, M. W., J. HETEROCYCL. CHEM., 1985, 22, N 5, 1203-1204
  作者：MAJCHRZAK, M. W.

  DOI：——

  日期：——
• Piperidylidene derivatives, their production and pharmaceutical compositions containing them
  申请人：SANDOZ AG

  公开号：EP0047226B1

  公开（公告）日：1985-05-15
• Heterocyclic Tetracyclic Tetrahydrofuran Derivatives As 5Ht2 Inhibitors In The Treatment Of Cns Disorders
  申请人：Cid-Nunez Maria Jose

  公开号：US20080108599A1

  公开（公告）日：2008-05-08

  This invention concerns novel substituted heterocyclic tetracyclic tetrahydrofuran derivatives with binding affinities towards serotonin receptors, in particular 5-HT 2A and 5-HT 2C receptors, and towards dopamine receptors, in particular dopamine D 2 receptors and with norepinephrine reuptake inhibition properties, pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim 1.
• HETEROCYCLIC TETRACYCLIC TETRAHYDROFURAN DERIVATIVES
  申请人：Cid-Núñez José Maria

  公开号：US20110144094A1

  公开（公告）日：2011-06-16

  This invention concerns novel substituted heterocyclic tetracyclic tetrahydrofuran derivatives with binding affinities towards serotonin receptors, in particular 5-HT 2A and 5-HT 2C receptors, and towards dopamine receptors, in particular dopamine D 2 receptors and with norepinephrine reuptake inhibition properties, pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim 1.